-
7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoic acid
-
ChemBase ID:
153578
-
Molecular Formular:
C23H29F3O6
-
Molecular Mass:
458.4679696
-
Monoisotopic Mass:
458.19162331
-
SMILES and InChIs
SMILES:
c1cc(cc(c1)OC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C/CCCC(=O)O)O)O)O)C(F)(F)F
Canonical SMILES:
OC(=O)CCC/C=C/C[C@H]1[C@@H](O)C[C@H]([C@@H]1C=C[C@H](COc1cccc(c1)C(F)(F)F)O)O
InChI:
InChI=1S/C23H29F3O6/c24-23(25,26)15-6-5-7-17(12-15)32-14-16(27)10-11-19-18(20(28)13-21(19)29)8-3-1-2-4-9-22(30)31/h1,3,5-7,10-12,16,18-21,27-29H,2,4,8-9,13-14H2,(H,30,31)/t16-,18-,19-,20+,21-/m1/s1
InChIKey:
WWSWYXNVCBLWNZ-LELZANKISA-N
-
Cite this record
CBID:153578 http://www.chembase.cn/molecule-153578.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
|
IUPAC name
|
|
7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoic acid
|
|
|
|
|
IUPAC Traditional name
|
|
7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoic acid
|
|
|
|
|
Synonyms
|
|
(+)-9α,11α,15R-Trihydroxy-16-[3-(trifluoromethyl)phenoxy]-17,18,19,20-tetranorprosta-5Z,13E-dien-1-oic acid
|
|
(+)-16-(m-Trifluoromethylphenoxy)tetranorprostaglandin F2α
|
|
(+)-Fluprostenol
|
|
|
|
|
EC Number
|
|
|
MDL Number
|
|
|
PubChem SID
|
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
|
Acid pKa
|
4.3552938
|
H Acceptors
|
6
|
H Donor
|
4
|
LogD (pH = 5.5)
|
1.7469386
|
LogD (pH = 7.4)
|
-0.0021406882
|
Log P
|
2.9199162
|
Molar Refractivity
|
113.921 cm3
|
Polarizability
|
42.78994 Å3
|
Polar Surface Area
|
107.22 Å2
|
Rotatable Bonds
|
12
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
Sigma Aldrich
Sigma Aldrich -
F4176
|
Biochem/physiol Actions Metabolically stable analog of PGF2α ; potent FP prostanoid receptor agonist. The optically active enantiomer of fluprostenol. This product is expected to have twice the potency of (+/-)-fluprostenol. It inhibits PGF2α binding to human and rat FP receptors (IC50 values of 3.5 and 7.5 nM respectively). It is a more potent luteolytic agent than PGF2α in rat and also an inhibitor of rat adipose precursor differentiation in primary cultures (IC50 = 3 to 10 ×10-11 M). |
PATENTS
PATENTS
PubChem Patent
Google Patent